Non-clinical support

Developing an ATMP from the pre-clinical stage through to first in human (FIH) clinical trials is a complex process and requires the development of a robust non-clinical strategy. We strive to help academics, start-ups, and therapy developers with bespoke strategies to ensure effective translation of novel therapies through the non-clinical phases towards clinical trials.

With experience in all aspects of non-clinical studies, from designing proof-of-concept (POC) and efficacy studies, through to FIH supporting pivotal safety good laboratory practice (GLP) programmes, our team employ expert knowledge of the contract research organisation (CRO) landscape specialising in ATMPs and a comprehensive understanding of the ATMP development process to rapidly progress your therapy to the clinic and beyond.

Our capabilities

Our non-clinical team can help you address the in silico, in vitro and in vivo scientific and regulatory evidence to help streamline your therapy’s development in an ethical and regulatory compliant manner.

Benefit from our expertise in:

Non-clinical strategy design

Creating customised “route to clinic” and “route to market” plans for your ATMP
Structuring of in vitro approaches including advice on vector design
Design of POC, mode-of-action (MOA), and efficacy studies
Safety study design, management and support with implementation and monitoring of the studies
Due diligence of non-clinical programmes for out/in-licencing

Laboratory study design

Pivotal GLP study design along with CRO engagement to ensure that your strategy is expertly translated to support future Clinical Trial Authorisation (CTA) filing

Clinical trial preparation

Provide recommendations for a path to CTA and Investigational New Drug (IND) application, as well as Marketing Authorisation and Biologic License Application (MAA/BLA)

Risk assessment and gap analysis

Risk assessment of your candidate ATMP in the selected clinical indication
Gap analysis of your POC and safety data

Regulatory support and compliance

Expert support in the preparation of the non-clinical sections of regulatory documents, such as Briefing Document, Investigator’s Brochure, and Investigational Medicinal Product Dossier
Reporting of non-clinical studies to worldwide regulatory standards
Combined ATMP strategies (all safety aspects including International Organisation for Standardisation (ISO) compliant medical device strategies)

Facilitating interactions with regulators

Supporting our collaborators in their interactions with Regulatory Authorities (MHRA/EMA/FDA), Scientific Advice, Innovation Office and INTERACT meetings

Working on a cell or gene therapy innovation challenge?

Contact